| Today's Big NewsMar 16, 2023 |
|
April 3 - 4, 2023 | San Diego, CA This event will focus on how to wear multiple hats in a communications role and how to work with stakeholders to succeed. Register Today!
|
|
| By Gabrielle Masson When it comes to getting women's health therapies to market, nothing is ever straightforward. From encouraging women to "step forward" for clinical trials to battling for R&D funding, it remains a tough arena—yet Organon is building a pipeline to mount a challenge. |
|
|
|
By Nick Paul Taylor Vaxart is pulling back from its oral COVID-19 vaccine program. Rather than pump more money into the pandemic project, the oral recombinant vaccine specialist will prioritize its norovirus prospect, extending its cash runway and laying off 27% of its staff in the process. |
By Nick Paul Taylor The ticking cash clock has forced IMV to act. Down to its last $21 million, the clinical-phase biotech has brought Stonegate Healthcare Partners onboard to explore strategic alternatives amid concerns about its ability to continue as a going concern. |
Sponsored by Thermo Fisher Scientific In the development of mRNA vaccines and therapeutics, identifying a raw materials supplier who can partner with you from preclinical to commercial supply is a key to success. |
By James Waldron Riding high from a cancer-focused deal with AbbVie, Immunome has become the latest biotech to decide that an investigational COVID-19 therapy is no longer one of its pipeline priorities. |
By Helen Floersh The road to developing therapies for the cognitive impairments seen in Down syndrome is paved with preclinical successes and clinical failures. But upgrading to a new, more accurate mouse model could change that. |
By Joseph Keenan Bayer subsidiary BlueRock Therapeutics has signed with Rune Labs to use the neurology software and data platform company’s clinical trial tech to get a sharper picture of Parkinson’s patient activity and encourage better engagement in its study. |
By Angus Liu As Johnson & Johnson and partner Legend Biotech struggle to meet demand for their CAR-T therapy Carvykti in the U.S., the companies seem to be pacing themselves with launches outside of the key market. |
By Robert King CMS is seeing an "astronomical" number of surprise billing arbitration dispute requests, with some of them marked as ineligible, one official shared. |
By Andrea Park Only a few months after Medtronic completed its acquisition of cardiac device maker Affera, the nearly billion-dollar buyout is already paying off. |
By Fraiser Kansteiner Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years thanks to “serious breaches” of the organization’s code of practice. This marks just the eighth time in 40 years that ABPI has issued “such a significant sanction,” the group pointed out. |
By Dave Muoio Depending on the state, anywhere from 16% to 43% of patients didn't see a primary care doctor for their medical service during a seven-year study period, FAIR Health reported in a new analysis. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines. |
|
---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Connect with senior executives in Medical Affairs, MSL and IIT to share best practices. Save $200 when you register today!
|
|
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|